<DOC>
	<DOCNO>NCT02124746</DOCNO>
	<brief_summary>This open-label study determine long-term safety tolerability momelotinib previously enrol study participant primary myelofibrosis ( PMF ) , post-polycythemia vera myelofibrosis ( post-PV MF ) , post-essential thrombocythemia myelofibrosis ( post-ET MF ) , polycythemia vera ( PV ) , essential thrombocythemia ( ET ) , tolerate achieve stable disease well momelotinib treatment enrol previous clinical trial .</brief_summary>
	<brief_title>Long-term Safety Efficacy Momelotinib Subjects With Primary Myelofibrosis , Post-polycythemia Vera Myelofibrosis , Post-essential Thrombocythemia Myelofibrosis , Polycythemia Vera Essential Thrombocythemia</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Currently enrol study CCL09101E , YM387II02 , successfully complete 24 week study GSUS3521672 Able comprehend willing sign inform consent form Known hypersensitivity momelotinib , metabolite , formulation excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Post Polycythemia Vera Myelofibrosis</keyword>
	<keyword>Post Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>blood disorder</keyword>
</DOC>